MarketWatch Article RatingDSM-Firmenich Confirms Mid-Term Targets Despite Weak Vitamin Market Hitting 2023 Earnings -- Update
- Bias Rating
- Reliability
25% ReliableLimited
- Policy Leaning
2% Center
- Politician Portrayal
N/A
Continue For Free
Create your free account to see the in-depth bias analytics and more.
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates.
Bias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
49% : The Dutch nutrition, health and beauty company anticipates pro forma adjusted earnings before interest, taxes, depreciation and amortization for 2023 will come in between 1.8 billion and 1.9 billion euros ($1.97 billion-$2.08 billion)--compared with EUR2.275 billion for 2022--given the further deterioration of the vitamin market it saw in the second quarter and expectations that prices will remain low until the end of the year.*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.
